The Prentif contraceptive cervical cap: a contemporary study of its clinical safety and effectiveness.
Because they seemed to be an overlooked, underutilized, and underdeveloped means of contraception, cervical caps were offered to patients in a private gynecological practice and the first 413 acceptors were sent a detailed questionnaire about their experiences. The 371 who responded provided generous amounts of information helpful in assessing not only cap safety and effectiveness, which are dealt with herein, but also in assessing acceptability which is dealt with in the companion article that follows. With regard to safety considerations, "cervical erosion" was not found to contraindicate cap use and no other significant safety hazards were encountered, although two concerns were suggested for further evaluation. The failure rate was 8.4 per 100 women per year by the life table method. Of 25 failures, 11 were labeled method failures and 14 were labeled human failures by the respondents themselves. The role of cap dislodgement as a cause of method failures is analyzed. It is concluded that caps are as safe and effective as diaphragms and that for many women they are the most suitable form of contraception available. It is reasonable to expect that they will soon be able to be approved for general use.
D000328:Adult; D002584:Cervix Uteri / Q000293:injuries; D003274:Contraceptive Devices, Female / Q000009:adverse effects / Q000592:standards; D004715:Endometriosis / Q000209:etiology; D005260:Female; D006801:Humans; D008598:Menstruation; D011247:Pregnancy; D013089:Spermatocidal Agents / Q000008:administration & dosage / Q000009:adverse effects; D011795:Surveys and Questionnaires; D014552:Urinary Tract Infections / Q000453:epidemiology; D002579:Uterine Cervical Erosion / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000209:etiology
D013089:Spermatocidal Agents